A Preliminary Prospective Study Evaluating Efficacy And Safety Of Vildagliptin In Nonalcoholic Fatty Liver Disease (NAFLD) Patients With Type 2 Diabetes Mellitus
Phase of Trial: Phase II
Latest Information Update: 17 Dec 2016
At a glance
- Drugs Vildagliptin (Primary)
- Indications Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 17 Dec 2016 New trial record
- 19 Oct 2016 Status changed from active, no longer recruiting to completed, according to results presented at the 24th United European Gastroenterology Week.
- 19 Oct 2016 Results presented at the 24th United European Gastroenterology Week.